
CStone Pharmaceuticals, a Chinese clinical-stage biopharmaceutical company, has raised about HK$2.23 billion (US$284.09 million) in an initial public offering on the Hong Kong stock exchange on Tuesday, which makes it become the sixth pre-profit Chinese biotech company to float shares in the financial hub.

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!